Can MRI of the Prostate Combined With a Radiomics Evaluation Determine the Invasive Capacity of a Tumour

Recruiting now · Not applicable

Conditions studied: Prostate Cancer

In brief

Prostate cancer is the most common cancer diagnosed in men in Canada. Magnetic resonance imaging (MRI) may become a valuable tool to non-invasively identify prostate cancer and assess its biological aggressiveness, which in turn will help doctors make better decisions about how to treat an individual patient's prostate cancer. Despite the promise of MRI for detecting and characterizing prostate cancer, there are several recognized limitations and challenges. These include lack of standardized interpretation and reporting of prostate MRI exams. The investigators propose to validate and improve a computer program computerized prediction tool that will use information from MR images to inform us how aggressive a prostate cancer is. The hypothesis is that this computer-aided approach will increase the reproducibility and accuracy of MRI in predicting the tumor biology information about the imaged prostate cancer.

Key facts

Study ID

NCT05024162

Run by

Nova Scotia Health Authority

People needed

60

Starts

2022-01-04

Expected to finish

2025-09-01

Last updated by the study team

2024-08-21

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• An appropriate diagnostic MRI-P, defined as:
• Being performed on 3T MRI at the Halifax Infirmary Building
• Taken place within 5 weeks of study enrolment
• Having a detectable nodule which anatomically localizes to prostate cancer (PCa) identified in diagnostic biopsy specimen
• Acquired T1+contrast, T2, and attenuated diffusion coefficient (ADC) series axial images of the prostate
• An appropriate diagnostic biopsy, defined as:
• Taken place within 2 months of the participant's MRI-P 1
• Taken place within 3 months of participant's study enrolment
• Reports diagnosis of PCa
• Reports a systematic assessment of the biopsy, assessing at least 12 cores
• Reports at least on core involved with PCa and this core must anatomically localise to a nodule seen on MRI-P 1

You may not qualify if…

• Past prostatic interventions which would influence the prostate's structure
• Alterations to physiological testosterone levels
• Inability to position one's self in a reproducible fashion for an MRI-P
• Patient factors reported to produce significant artifact on MRI-P 1

Where it is running

• Victoria General Hospital — Halifax, Nova Scotia, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.